Cobra Biologics Limited Sustainability Profile
Cobra Biologics Limited, a leading contract development and manufacturing organisation (CDMO), is headquartered in the United Kingdom. Established in 2003, Cobra has made significant strides in the biopharmaceutical industry, specialising in the production of plasmid DNA, viral vectors, and cell line development. With operational facilities in both the UK and Sweden, the company serves a global clientele, providing tailored solutions for gene therapy and vaccine development. Cobra's core offerings include high-quality plasmid DNA and viral vector production, distinguished by their commitment to stringent quality standards and regulatory compliance. The company has achieved notable milestones, including successful collaborations with prominent biotech firms, solidifying its position as a trusted partner in the biomanufacturing landscape. With a focus on innovation and customer-centric services, Cobra Biologics continues to play a pivotal role in advancing biopharmaceutical development.
DitchCarbon Score
How does Cobra Biologics Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cobra Biologics Limited's score of 62 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cobra Biologics Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Charles River Laboratories International, Inc., which means that any climate commitments or emissions data may be inherited from this parent organization. Cobra Biologics Limited is aligned with several climate initiatives through its relationship with Charles River Laboratories. This includes participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded from Charles River Laboratories at a third-level corporate relationship. However, specific reduction targets or achievements for Cobra Biologics are not detailed in the available information. As a subsidiary, Cobra Biologics is expected to adhere to the sustainability and climate commitments set forth by its parent company, which may include broader corporate goals aimed at reducing carbon emissions and enhancing environmental responsibility. Without specific emissions data or reduction targets, the company's current climate commitments remain vague, but they are part of a larger corporate strategy focused on sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,284,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 79,271,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Cobra Biologics Limited's Industry?
How Carbon Intensive is Cobra Biologics Limited's Location?
Cobra Biologics Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cobra Biologics Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
